Login to Your Account


PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based Recce Pharmaceuticals Ltd. that could solve the problem of antibiotic resistance.

PERTH, Australia – Sydney-based Kazia Therapeutics Ltd. has begun a U.S. phase II trial in glioblastoma with lead candidate GDC-0084, in-licensed from Roche Holding AG unit Genentech.

SHANGHAI – One-year-old Terns Pharmaceuticals will seed its pipeline with three candidates for nonalcoholic steatohepatitis (NASH), having acquired global development and commercialization rights from Eli Lilly & Co., of Indianapolis. Terns intends to take a China-first strategy for the development and registration of these candidates for liver disease while remaining open to global opportunities.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: